SMT201600041B - Agenti terapeutici 713 - Google Patents

Agenti terapeutici 713

Info

Publication number
SMT201600041B
SMT201600041B SM201600041T SM201600041T SMT201600041B SM T201600041 B SMT201600041 B SM T201600041B SM 201600041 T SM201600041 T SM 201600041T SM 201600041 T SM201600041 T SM 201600041T SM T201600041 B SMT201600041 B SM T201600041B
Authority
SM
San Marino
Prior art keywords
therapeutic agents
therapeutic
agents
Prior art date
Application number
SM201600041T
Other languages
English (en)
Inventor
Lars Anders Mikael Johansson
Robert Andrew Judkins
Lanna Li
Bjorn Christian Ingvar Lofberg
Joachim Persson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SMT201600041B publication Critical patent/SMT201600041B/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SM201600041T 2009-05-01 2016-02-11 Agenti terapeutici 713 SMT201600041B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17463009P 2009-05-01 2009-05-01
PCT/GB2010/050698 WO2010125390A1 (en) 2009-05-01 2010-04-29 Therapeutic agents 713

Publications (1)

Publication Number Publication Date
SMT201600041B true SMT201600041B (it) 2016-02-25

Family

ID=42290768

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600041T SMT201600041B (it) 2009-05-01 2016-02-11 Agenti terapeutici 713

Country Status (23)

Country Link
US (1) US8110566B2 (it)
EP (1) EP2424870B1 (it)
JP (1) JP5763052B2 (it)
KR (1) KR20120023044A (it)
CN (2) CN103936751A (it)
AR (1) AR076516A1 (it)
AU (1) AU2010243341B2 (it)
BR (1) BRPI1014387A2 (it)
CA (1) CA2759230A1 (it)
DK (1) DK2424870T3 (it)
ES (1) ES2562831T3 (it)
HR (1) HRP20160128T1 (it)
HU (1) HUE026856T2 (it)
MX (1) MX2011011618A (it)
PL (1) PL2424870T3 (it)
PT (1) PT2424870E (it)
RU (1) RU2526055C2 (it)
SA (1) SA110310332B1 (it)
SI (1) SI2424870T1 (it)
SM (1) SMT201600041B (it)
TW (1) TW201100433A (it)
UY (1) UY32593A (it)
WO (1) WO2010125390A1 (it)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049864A1 (en) * 2006-10-25 2008-05-02 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
MX2012015102A (es) 2010-07-06 2013-05-01 Astrazeneca Ab Agentes terapeuticos 976.
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
HU230880B1 (hu) 2015-04-15 2018-11-29 Richter Gedeon Nyrt Indol származékok
JP2022525186A (ja) 2019-03-15 2022-05-11 ザ ジェネラル ホスピタル コーポレイション Tead転写因子新規小分子阻害剤
CN115350184A (zh) * 2020-01-10 2022-11-18 康圣博施医药有限公司 药物的治疗组合以及其使用方法
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0306980A (pt) * 2002-02-01 2004-11-09 Novo Nordisk As Composto, uso de um composto, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com o receptor de histamina h3
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
WO2004011440A1 (ja) * 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
US7601868B2 (en) 2003-02-12 2009-10-13 Takeda Pharmaceutical Company Limited Amine derivative
US20060293298A1 (en) * 2003-04-10 2006-12-28 Bamford Mark J Compounds
GB0400193D0 (en) 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
EP1706384A1 (en) 2004-01-07 2006-10-04 AstraZeneca AB Therapeutic agents i
US7241787B2 (en) * 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
TW200538098A (en) * 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
WO2006019833A1 (en) * 2004-07-26 2006-02-23 Eli Lilly And Company Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
US7846950B2 (en) 2004-10-18 2010-12-07 Eli Lilly And Company Histamine H3 receptor inhibitors, preparation and therapeutic uses
CN101072775A (zh) 2004-12-17 2007-11-14 伊莱利利公司 新的mch受体拮抗剂
EP1831194A4 (en) * 2004-12-21 2009-12-02 Astrazeneca Ab HETEROCYCLIC ANTAGONISTS OF MCHr1 AND THERAPEUTIC APPLICATIONS THEREOF
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
KR20080011677A (ko) 2005-05-31 2008-02-05 아스트라제네카 아베 신규 mchr1 길항제 및 그의 mchr1 매개된 상태 및장애의 치료를 위한 용도
WO2007011284A1 (en) 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
CN101400677A (zh) 2006-01-06 2009-04-01 阿斯利康(瑞典)有限公司 化合物
AU2007275301A1 (en) 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
EP2121703A4 (en) * 2006-08-18 2011-12-28 Astrazeneca Ab THIENOPYRIMIDIN-4-ON- AND THIENOPYRIDAZIN-7-ONDERIVATES AS MCH-RL ANTAGONISTS
JP5290192B2 (ja) 2006-12-05 2013-09-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Mch−1に媒介される疾患における使用のための新規な置換されたジアザ−スピロ−ピリジノン誘導体
KR20090082484A (ko) 2006-12-14 2009-07-30 일라이 릴리 앤드 캄파니 5-[4-(아제티딘-3-일옥시)-페닐]-2-페닐-5h-티아졸로[5,4-c]피리딘-4-온 유도체 및 mch 수용체 길항제로서의 이들의 용도
JP2010524962A (ja) 2007-04-17 2010-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド オーロラキナーゼ阻害剤のための創薬法
AU2008290634B2 (en) 2007-08-22 2012-12-06 F. Hoffmann-La Roche Ag Pyrrolidine aryl-ether as NK3 receptor antagonists
MY151348A (en) * 2007-10-17 2014-05-15 Sanofi Aventis Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
JPWO2009154132A1 (ja) * 2008-06-19 2011-12-01 Msd株式会社 スピロジアミン−ジアリールケトオキシム誘導体

Also Published As

Publication number Publication date
PL2424870T3 (pl) 2016-05-31
ES2562831T3 (es) 2016-03-08
CN102459279B (zh) 2014-06-25
KR20120023044A (ko) 2012-03-12
JP2012525365A (ja) 2012-10-22
CN103936751A (zh) 2014-07-23
AU2010243341B2 (en) 2014-02-13
US20100280000A1 (en) 2010-11-04
TW201100433A (en) 2011-01-01
AR076516A1 (es) 2011-06-15
US8110566B2 (en) 2012-02-07
EP2424870B1 (en) 2015-12-16
JP5763052B2 (ja) 2015-08-12
DK2424870T3 (en) 2016-02-15
UY32593A (es) 2010-11-30
SA110310332B1 (ar) 2013-12-10
SI2424870T1 (sl) 2016-03-31
AU2010243341A1 (en) 2011-11-03
WO2010125390A1 (en) 2010-11-04
HRP20160128T1 (hr) 2016-02-26
BRPI1014387A2 (pt) 2017-06-06
CN102459279A (zh) 2012-05-16
EP2424870A1 (en) 2012-03-07
CA2759230A1 (en) 2010-11-04
HUE026856T2 (en) 2016-07-28
PT2424870E (pt) 2016-03-17
RU2526055C2 (ru) 2014-08-20
MX2011011618A (es) 2011-11-18

Similar Documents

Publication Publication Date Title
BRPI0916931A2 (pt) agentes terapêuticos
DK2144905T3 (da) Terapeutiske midler
BR112012004546A2 (pt) "terapêutica por proteínas ligantes dll4-ligantes"
SMT201500053B (it) 2-Amminobenzimidazol-5-carbossammidi come agenti nati-infiammatori
BR112012012872A2 (pt) "pirrolindinas de espiroindolinona"
BRPI1010909A2 (pt) "inseticida arilpirrolinas"
PT2448582T (pt) Compostos e composições terapêuticas
BRPI1012004A2 (pt) "forma farmacêutica"
GB0811304D0 (en) Therapeutic agents
EP2471786A4 (en) aminopyrazole derivative
BRPI1013015A2 (pt) "osteosíntese com nanoprata"
DK2185142T3 (da) Antiseptiske midler
GB0819593D0 (en) Therapeutic agents
GB0801081D0 (en) Therapeutic agents
GB0821693D0 (en) Therapeutic agents
GB0801080D0 (en) Therapeutic agents
GB0812309D0 (en) Therapeutic agents
BRPI0818598A2 (pt) agentes terapêuticos - 802
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
GB0805818D0 (en) Therapeutic agents
GB0724340D0 (en) Novel Therapeutic Agents
SI2424870T1 (sl) Terapevtska sredstva 713
EP2454248A4 (en) ANTI FLU RESOURCES
BRPI1006474A2 (pt) "gatilho"
BRPI0909764A2 (pt) compostos terapêuticos